About
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to...
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and other diseases. The Company has a, diversified portfolio of cell and biologic therapies at different stages ranging from pre-clinical programs in immunomodulation to mid-to-late stage clinical development for orthopedic conditions, targeting markets with large unmet medical needs and limited innovation. Bone Therapeutics is developing an off-the-shelf next-generation improved viscosupplement, JTA-004, which is currently in phase III development for the treatment of pain in knee osteoarthritis. Consisting of a unique combination of plasma proteins, hyaluronic acid - a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain and inflammation. Positive phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. Bone Therapeutics’ core technology is based on its cutting-edge allogeneic cell therapy platform with differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs) which can be stored at the point of use in the hospital. Currently in pre-clinical development, BT-20, the most recent product candidate from this technology, targets inflammatory conditions, while the leading investigational medicinal product, ALLOB, represents a unique, proprietary approach to bone regeneration, which turns undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced via the Bone Therapeutics’ scalable manufacturing process. Following the CTA approval by regulatory authorities in Europe, the Company is ready to start the phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. ALLOB continues to be evaluated for other orthopedic indications including spinal fusion, osteotomy, maxillofacial and dental.
  • 30
    Oct
    20
    News Release
    Bone Therapeutics Provides Third Quarter 2020 Business Update
  • 29
    Oct
    20
    News Release
    Bone Therapeutics and Catalent sign agreements to streamline production of the allogeneic cell therapy product, ALLOB
  • 23
    Oct
    20
    News Release
    Transparency notification received from S.R.I.W. SA and Sofipôle SA
  • 23
    Oct
    20
    News Release
    Information on the total number of voting rights and shares
  • 20
    Oct
    20
    News Release
    Bone Therapeutics reaches 50% treated patients in ongoing JTA-004 Phase III pivotal knee osteoarthritis study
  • 14
    Oct
    20
    News Release
    Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa
  • 14
    Oct
    20
    News Release
    Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
  • 5
    Oct
    20
    News Release
    Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia
  • 28
    Sep
    20
    Equity Research
    Bone Therapeutics (EBR:BOTHE) Research Update
  • 15
    Sep
    20
    Company Presentation
    Bone Therapeutics Corporate Presentation
  • 9
    Sep
    20
    News Release
    Information on the total number of voting rights and shares
  • 27
    Aug
    20
    Company Presentation
    Bone Therapeutics Corporate Presentation
  • 26
    Aug
    20
    News Release
    Bone Therapeutics reports half year 2020 results
  • 20
    Aug
    20
    News Release
    Bone Therapeutics announces expansion of its pipeline supported by funding from the Walloon Region
  • 13
    Aug
    20
    News Release
    Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study
  • 22
    Jun
    20
    Equity Research
    Bone Therapeutics (EBR:BOTHE) Research Update
  • 11
    Jun
    20
    News Release
    Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020
  • 29
    May
    20
    News Release
    Transparency notification received from S.R.I.W. SA and Sofipôle SA
  • 29
    May
    20
    News Release
    Information on the total number of voting rights and shares
  • 19
    May
    20
    News Release
    Bone Therapeutics treats first patients in pivotal JTA-004 phase III knee osteoarthritis study
  • 11
    May
    20
    News Release
    Bone Therapeutics to host Annual Ordinary General Meeting on 10 June 2020
  • 7
    May
    20
    News Release
    Bone Therapeutics raises additional EUR 4.0 million, with total of EUR 15.0 million committed, providing runway into Q2 2021
  • 6
    May
    20
    News Release
    Bone Therapeutics Provides First Quarter 2020 Business Update
  • 29
    Apr
    20
    News Release
    Bone Therapeutics secures EUR 11.0 million financing
  • 29
    Apr
    20
    Corporate Update
    Financial Report 2019
  • 3
    Apr
    20
    Corporate Update
    Information on the total number of voting rights and shares
  • 23
    Mar
    20
    News Release
    Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates
  • 11
    Mar
    20
    News Release
    Bone Therapeutics announces 2019 full year results
  • 28
    Feb
    20
    News Release
    Information on the total number of voting rights and shares
  • 11
    Feb
    20
    News Release
    Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at the Annual Meeting of the Orthopaedic Research Society (ORS)
  • 11
    Feb
    20
    Equity Research
    Bone Therapeutics (EBR:BOTHE) Research Initiation
  • 31
    Jan
    20
    News Release
    Information on the total number of voting rights and shares
  • 22
    Jan
    20
    News Release
    Bone Therapeutics announces 2020 business outlook and reports year-end 2019 cash position
  • 22
    Jan
    20
    Company Presentation
    Company presentation January 2020
  • 9
    Jan
    20
    News Release
    Bone Therapeutics announces attendance at the 38 the Annual J.P. Morgan Healthcare Conference
  • 31
    Dec
    19
    Company Presentation
    Company presentation December 2019
  • 30
    Dec
    19
    News Release
    Information on the total number of voting rights and shares
  • 20
    Dec
    19
    News Release
    Bone Therapeutics advances JTA-004 into pivotal Phase III study
  • 19
    Dec
    19
    News Release
    Bone Therapeutics announces the appointment of Dr. Miguel Forte as CEO to lead the Company into the next phase of development
  • 9
    Dec
    19
    News Release
    Transparency notification received from S.R.I.W. SA and Sofipôle SA
  • 29
    Nov
    19
    News Release
    Information on the total number of voting rights and shares
  • 25
    Nov
    19
    News Release
    The preliminary documents for the Extraordinary General Shareholder Meeting on 12 December 2019 have been made available
  • 6
    Nov
    19
    News Release
    Bone Therapeutics Reports Financial Results for the First Nine Months of 2019 and Provides Third Quarter 2019 Business Update
  • 31
    Oct
    19
    Company Presentation
    Company Presentation
  • 2
    Oct
    19
    News Release
    Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27 th Annual Meeting of the European Orthopaedic Research Society
  • 27
    Sep
    19
    News Release
    Bone Therapeutics to present data from its Phase II/III trial with JTA-004 at the 2nd World Congress on Rheumatology & Orthopedics
  • 30
    Aug
    19
    Corporate Update
    Interim Financial Report H1 2019
  • 30
    Aug
    19
    Company Presentation
    H1 2019 Results
  • 30
    Aug
    19
    News Release
    Bone Therapeutics reports half year 2019 results
  • 13
    Jun
    19
    News Release
    Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure
  • 12
    Jun
    19
    News Release
    Bone Therapeutics announces results of Annual General Meeting
  • 24
    May
    19
    News Release
    Bone Therapeutics to present data at TERMIS European Chapter Meeting 2019
  • 7
    May
    19
    News Release
    Bone Therapeutics Provides First Quarter 2019 Business Update
  • 25
    Apr
    19
    Corporate Update
    Annual Report 2018
  • 25
    Apr
    19
    Corporate Update
    Business Overview 2018
  • 12
    Mar
    19
    News Release
    Bone Therapeutics appoints Olivier Godeaux as Chief Medical Officer and Benoit Moreaux as Chief Scientific and Technology Officer
  • 1
    Mar
    19
    Company Presentation
    Annual Results 2018
  • 1
    Mar
    19
    News Release
    Bone Therapeutics announces 2018 full year results
  • 22
    Jan
    19
    News Release
    Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position
  • 30
    Aug
    18
    Corporate Update
    Interim Financial Report H1 2018
  • 25
    Apr
    17
    Corporate Update
    Business Overview 2018